Karyopharm Therapeutics | KPTI - Loan Capital


Karyopharm Therapeutics reported $264.49M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Abbott USD 29.64B 19.74B Mar/2026
Amgen USD 51.86B 27M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Incyte USD 28.42M 994K Jun/2026
J&J USD 37.34B 183M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Novartis USD 37.49B 42M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.5B 70M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Takeda JPY 4.42T 50.32B Jun/2026
Tectonic Therapeutic USD 17K 26K Mar/2026
TG Therapeutics USD 745.39M 247K Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Xencor USD 77.54M 4.59M Jun/2026